Raymond Prudo-Chlebosz - Mar 6, 2025 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)

Role
Director
Signature
/s/ Torsten Hombeck, as Attorney-in-Fact
Stock symbol
AKTX
Transactions as of
Mar 6, 2025
Transactions value $
$1,499,998
Form type
4
Date filed
3/10/2025, 05:00 PM
Previous filing
Dec 3, 2024
Next filing
Mar 24, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKTX American Depositary Shares representing Ordinary Shares Award $500K +446K +21.9% $1.12 2.48M Mar 6, 2025 Direct F1, F2
holding AKTX American Depositary Shares representing Ordinary Shares 19.4K Mar 6, 2025 Praxis Trustees Limited F1
holding AKTX American Depositary Shares representing Ordinary Shares 400K Mar 6, 2025 RPC Pharma Limited F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKTX Series A Warrants (Right to Buy) Award $500K +446K $1.12 446K Mar 6, 2025 American Depositary Shares representing Ordinary Shares 446K $0.87 Direct F1, F2
transaction AKTX Series B Warrants (Right to Buy) Award $500K +446K $1.12 446K Mar 6, 2025 American Depositary Shares representing Ordinary Shares 446K $0.87 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.
F2 On March 6, 2025, the Reporting Person acquired 446,428 ADS and accompanying Series A and Series B warrants to purchase up to 892,856 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant.

Remarks:

Exhibit 24 - Power of Attorney